Background: Non–vitamin K oral anticoagulants have become the standard therapy for
preventing stroke and ischemic thromboembolism in most patients with atrial fibrillation (AF) …

Background: There are no randomized data evaluating the safety or efficacy of apixaban for
stroke prevention in patients with end-stage kidney disease on hemodialysis and with atrial …

Introduction Patients with end-stage kidney disease requiring maintenance haemodialysis
treatment experience a dramatic cardiovascular morbidity and mortality. Due to the high …

Background: Compared with the general population, patients with advanced chronic kidney
disease have a> 10-fold higher burden of atrial fibrillation. Limited data are available …

Background: Current guidelines make no specific recommendations on the selection of
direct oral anticoagulants for the prevention and treatment of venous thromboembolism in …

Background At the present, apixaban is the only nonvitamin K oral anticoagulant approved
by the Food and Drug Administration for use with patients with creatinine clearance< 15 …

Background: Patients with end-stage kidney disease (ESKD) on dialysis were excluded from
clinical trials of direct oral anticoagulants for atrial fibrillation (AF). Recent data have raised …

BACKGROUND: Recommendations for apixaban dosing on the basis of kidney function are
inconsistent between the US Food and Drug Administration and European Medicines …

Background: Because of a lack of comparative data on anticoagulant use in the advanced
chronic kidney disease (CKD) population, guidelines recommend warfarin for atrial …

Background: Warfarin has been the cornerstone of therapy for patients with stage 4 and 5
chronic kidney disease (CKD) requiring anticoagulation. These patients were omitted from …